SCHEMBL7805391

SCHEMBL7805391

Cc1cc(Br)cc2c1n[c]n2C

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ NQO2 P16083 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7812265 0.74 — —
SCHEMBL3323208 0.69 TLR8 (0.37) —
SCHEMBL7814408 0.68 NPM1 (0.35) —
SCHEMBL16244381 0.68 NQO2 (0.37) NQO2
SCHEMBL25105335 0.68 NQO2 (0.41) NQO2
SCHEMBL7817980 0.64 NPC1 (0.40) —
SCHEMBL23809859 0.63 NQO2 (0.40) NQO2
SCHEMBL15112190 0.61 BRD4 (0.40) NQO2
SCHEMBL7812397 0.61 NQO2 (0.36) NQO2
SCHEMBL21522868 0.61 NQO2 (0.38) NQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0745600-B1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2001-10-24 — — EP disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 — — US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 — — EP disclosed
Send feedback